Scorpius Holdings, Inc. (SCPX)
USD 0.12
(-7.15%)
USD 0.12
(-7.15%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 51.03 Million USD | -51.11% |
| 2022 | 104.39 Million USD | -13.69% |
| 2021 | 120.96 Million USD | -2.6% |
| 2020 | 124.19 Million USD | 130.73% |
| 2019 | 53.82 Million USD | -11.3% |
| 2018 | 60.68 Million USD | 200.57% |
| 2017 | 20.18 Million USD | 126.93% |
| 2016 | 8.89 Million USD | -32.69% |
| 2015 | 13.21 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 50.5 Million USD | -1.05% |
| 2024 Q2 | 46.68 Million USD | -7.55% |
| 2023 Q1 | 91.51 Million USD | -34.97% |
| 2023 Q4 | 51.03 Million USD | -27.0% |
| 2023 Q3 | 69.91 Million USD | -12.81% |
| 2023 FY | 51.03 Million USD | -51.11% |
| 2023 Q2 | 80.18 Million USD | -12.38% |
| 2022 Q4 | 140.72 Million USD | 17.11% |
| 2022 Q3 | 120.16 Million USD | -8.87% |
| 2022 Q2 | 131.85 Million USD | 15.39% |
| 2022 Q1 | 114.26 Million USD | -21.01% |
| 2022 FY | 104.39 Million USD | -13.69% |
| 2021 Q3 | 132.65 Million USD | -4.42% |
| 2021 FY | 120.96 Million USD | -2.6% |
| 2021 Q2 | 138.78 Million USD | -3.93% |
| 2021 Q4 | 144.66 Million USD | 9.05% |
| 2021 Q1 | 144.47 Million USD | 0.0% |
| 2020 FY | 124.19 Million USD | 130.73% |
| 2019 FY | 53.82 Million USD | -11.3% |
| 2018 FY | 60.68 Million USD | 200.57% |
| 2017 FY | 20.18 Million USD | 126.93% |
| 2016 FY | 8.89 Million USD | -32.69% |
| 2015 FY | 13.21 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 19.38 Million USD | -163.338% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -789.777% |
| Armata Pharmaceuticals, Inc. | 109.96 Million USD | 53.587% |
| Actinium Pharmaceuticals, Inc. | 81.44 Million USD | 37.335% |
| Azitra, Inc. | 5.11 Million USD | -897.708% |
| Can-Fite BioPharma Ltd. | 9.98 Million USD | -410.938% |
| Chromocell Therapeutics Corporation | 96.39 Thousand USD | -52848.54% |
| Calidi Biotherapeutics, Inc. | 10.01 Million USD | -409.408% |
| CEL-SCI Corporation | 30.52 Million USD | -67.182% |
| iBio, Inc. | 28.73 Million USD | -77.621% |
| Lineage Cell Therapeutics, Inc. | 101.01 Million USD | 49.477% |
| MAIA Biotechnology, Inc. | 7.56 Million USD | -574.49% |
| Matinas BioPharma Holdings, Inc. | 65.57 Million USD | 22.173% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -1067.48% |
| NovaBay Pharmaceuticals, Inc. | 9.03 Million USD | -464.95% |
| NanoViricides, Inc. | 12.82 Million USD | -298.021% |
| Oragenics, Inc. | 4.96 Million USD | -927.672% |
| BiomX Inc. | 58.15 Million USD | 12.24% |
| BiomX Inc. | 58.15 Million USD | 12.24% |
| Protalix BioTherapeutics, Inc. | 84.43 Million USD | 39.553% |
| Palatin Technologies, Inc. | 10.74 Million USD | -375.11% |
| Theriva Biologics, Inc. | 60.21 Million USD | 15.235% |